Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 5.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 90,800 shares of the company’s stock after buying an additional 4,600 shares during the period. Canada Pension Plan Investment Board’s holdings in Omnicell were worth $2,458,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares in the last quarter. EntryPoint Capital LLC lifted its stake in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares in the last quarter. CWM LLC boosted its holdings in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. grew its position in shares of Omnicell by 36.4% in the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Omnicell in the second quarter valued at approximately $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Down 0.5 %

Shares of NASDAQ OMCL opened at $42.33 on Friday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $46.47. The business’s 50 day moving average is $40.15 and its two-hundred day moving average is $32.60. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -92.02, a PEG ratio of 48.57 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.29 EPS. Research analysts predict that Omnicell, Inc. will post 0.64 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on OMCL shares. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Wells Fargo & Company upped their price objective on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Bank of America lifted their target price on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. increased their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Finally, Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Omnicell currently has a consensus rating of “Hold” and an average target price of $37.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.